Cardiol Therapeutics Inc (nasdaq:CRDL) Share Price

Company Profile

Business description
Cardiol Therapeutics Inc is a clinical-stage life sciences company focused on the research and clinical development of anti-inflammatory and anti-fibrotic therapies for the treatment of heart diseases. The company's main product candidate, CardiolRx, is a pharmaceutically manufactured oral cannabidiol formulation that is being clinically developed for use in heart diseases. Cardiol has received Investigational New Drug Application authorization from the United States Food and Drug Administration to conduct clinical studies to evaluate the efficacy and safety of CardiolRx in two diseases affecting the heart which are a Phase II multi-national trial, the ARCHER trial, in acute myocarditis; and a Phase II multi-center open-label pilot study in recurrent pericarditis.
Contact
2265 Upper Middle Road East
Suite 602
OakvilleONL6H 0G5
CAN
T: +1 289 910-0850
E: [email protected]
https://www.cardiolrx.com
Sector
Healthcare
Stock type
Defensive
Industry
Drug Manufacturers - Specialty & Generic
Fiscal Year End
31 December 2025
Employees
18

Recommended

We doubt the $5 billion is meaningful enough to force Nvidia to use Intel, either for core products or even for the chips in collaboration.

Brian Colello, CPA | 19 September 2025

Our Fair Value estimate once again reflects the stand-alone business and its growth potential.

Mark Taylor | 19 September 2025

Coverage of ASX listed REIT as investor interest in property continues to grow.

Yingqi Tan, CFA | 19 September 2025

Index	Last price	Change	% Change
All Ordinaries	9,061.20	20.50	-0.23%
CAC 40	7,853.59	1.02	-0.01%
DAX 40	23,639.41	35.12	-0.15%
Dow JONES (US)	46,287.23	144.81	0.31%
FTSE 100	9,216.67	11.44	-0.12%
HKSE	26,545.10	0.25	0.00%
NASDAQ	22,571.17	100.45	0.45%
Nikkei 225	45,045.81	257.62	-0.57%
NZX 50 Index	13,231.66	111.63	0.85%
S&P 500	6,652.43	20.47	0.31%
S&P/ASX 200	8,773.50	18.70	-0.21%
SSE Composite Index	3,820.09	11.57	-0.30%